knowledge -WSS

knowledge

author：Wikipedia 2025-09-27 09:40:42 - browse：3379

Teleflex announced plans on Wednesday to acquire Palette Life Sciences, the maker of a slate of gel-based products treating urological disorders. The vascular device manufacturer will pay $600 million upfront, and plans to use Palette’s portfolio to treat more urinary tract and reproductive health conditions.

Palette will bring Teleflex an extra $56 million in sales, the company estimated in a press release. Teleflex develops a range of devices, but makes the most money from vascular products like catheters. The company offers just one urological treatment: the UroLift system to relieve an enlarged prostate. With Palette, it will gain five more treatments all built from hyaluronic acid, a stretchy material that’s meant to last longer in the human body.

Palette’s highest-revenue device is Barrigel, which helps protect the rectum from harsh radiation administered to prostate cancer patients. It eases symptoms like bladder inflammation, bleeding, and diarrhea. The device received FDA clearance in May 2022 through the 510(k) process, which allowed Palette to claim the product was equivalent to a rectal radiation protector sold by Boston Scientific. Boston Scientific has sold that device since 2018, when it acquired it by buying the startup Augmenix for $500 million.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： United colonoscopy coverage change 'may cost lives,' doctors say
Next article： Congenital heart disease patients face new threat of heart failure

WSS

Suspect in Ukraine detonates explosives at a courthouse, killing himself and wounding 2 officers

Supreme Court shows surprising restraint in chaotic year of crises: ANALYSIS

Spinal cord stimulation reduces pain in amputees, study finds

Pharma patents targeted by Biden in move to slash drug prices

Chemotherapy shortages won’t get better under Biden’s latest plan

AbbVie buys Immunogen, maker of targeted cancer drugs, for $10B

entertainment

knowledge

explore

Medical records are filled with copy

Pharma patents targeted by Biden in move to slash drug prices

How one medical school became remarkably diverse

Condition critical? Britain's beloved but battered National Health Service turns 75

New air purifier tech could be key to improving indoor air quality

SCOTUS to consider access to abortion pill mifepristone

Walensky prepares to leave CDC — and Congress — behind

FDA needs staff influx to meet gene therapy needs, Marks says

As demand for Covid shots wanes, Moderna seeks its next success

Ph.D. graduate surprised with gift registry: 'You deserve to be celebrated'

hotspot

1 in 4 Americans hadn't contracted COVID by the end of 2022, CDC estimates

Ph.D. graduate surprised with gift registry: 'You deserve to be celebrated'

The woman behind the Dana Farber

CMS should re

A bus careens into a gulch in southern Mexico, leaving 27 people dead

What causes an itch? Researchers may have solved the mystery

focus

focus

Wikipedia

explore